BURNABY, British Columbia, March 25, 2016 /PRNewswire/ --
Increasing prevalence of osteoporosis and growing aging population coupled with new product launches to drive United States osteoporosis drugs market through 2021
According to Pharmaion report, "United States Osteoporosis Drugs Market Opportunities, 2011 - 2021", the osteoporosis drugs market in the US is projected to cross US$ 4 billion by 2021. Growth in the market is anticipated on account of increasing prevalence of osteoporosis, rising aging population and growing number of post-menopausal women. Moreover, increasing number of international players and growing awareness regarding osteoporotic care among consumers is projected to drive the osteoporosis drugs market in the United States over the next five years.
In 2011, According to the National Osteoporosis Foundation, 10 million individuals aged 50 years or above (2 million men and 8 million women) in the United States, were suffering from the disease. Additionally, almost 34 million individuals had low bone mass, which placed them at a high risk for developing osteoporosis. With growing aging population, the number of people suffering from osteoporosis is anticipated to increase to 14 million individuals, and more than 47 million cases of low bone mass are expected to be reported by 2020.
Growing adoption of generic products, patent expiry and various side-effects related to osteoporosis drugs are some of the major factors restraining growth of osteoporosis drugs market in the country. On the basis of drug class, the market has been segmented into six categories, namely, Bisphosphonates, Calcitonins, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone (PTH), Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) & others. Among these categories, Bisphosphonates dominated the United States osteoporosis drugs market in 2015. However, owing to patent expiries and associated side-effects of Bisphosphonates, RANKL is anticipated to emerge as the largest drug category by end of 2021.
"With growing adoption of Cathepsin K Inhibitors, Wnt Signaling Antibodies and Osteoblastic Cell Therapy, United States osteoporosis drugs market will continue to exhibit promising growth in the coming years. Moreover, various federal agencies in the United States are working towards setting up public workshops to discuss challenges and solutions related to osteoporosis drug development. These workshops offer a unified platform to clinicians, researchers and scientists to share their inputs for better osteoporosis drug development. All these factor present a positive outlook for osteoporosis drugs market, especially in the US." said Mr. Karan Chechi, Research Director with Pharmaion Consultants, a research based global management consulting firm focused on pharma and healthcare industry.
"United States Osteoporosis Drugs Market Opportunities, 2011 - 2021" has analyzed the potential of osteoporosis drugs market in the United States and provides statistics and information on market sizes, shares and trends. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyzes the emerging trends along with essential drivers and key challenges faced by the United States osteoporosis drugs market.
About Pharmaion
Pharmaion is a research based management consulting firm focused exclusively on Healthcare & Pharmaceutical industry. Led by a team of dynamic industry experts, Pharmaion provides its customers with high value market research and advisory services that helps them identify new market opportunities, growth engines and innovative ways to capture the market share. As a result, Pharmaion's clients lead rather than follow market trends. Pharmaion has developed a proprietary database which focuses on identifying the unexplored opportunities in Healthcare and Pharmaceutical industry.
Media Contact
Karan Chechi
Research Director
Contact Phone- +1 646 862 0089
Email- sales@pharmaion.com
